ublituximab

January 28, 2019

FDA Names Umbralisib ‘Breakthrough Therapy’ as Possible Treatment for Marginal Zone Lymphoma

News

The U.S. Food and Drug Administration (FDA) has designated umbralisib (TGR-1202), by TG Therapeutics, a breakthrough therapy as a possible treatment for adults with marginal zone lymphoma (MZL) who did not respond to at least one ... Read more

November 26, 2018

Phase 1 Study of BTK Inhibitor in Treating B-cell Blood Cancers Underway, TG Therapeutics Announces

News

A Phase 1 clinical trial, sponsored by TG Therapeutics, is recruiting patients with B-cell lymphoma or leukemia to study the company’s Bruton tyrosine kinase (BTK) inhibitor, TG-1701. The study is enrolling up ... Read more

August 16, 2017August 16, 2017

TGR-1202 and TG-1101 Combo Is Effective Enough Against Lymphoma to Continue Being Tested in Phase 2 Trial

News

A combination of two of TG Therapeutics’ lymphoma treatments proved effective enough to continue enrolling patients in a Phase 2b clinical trial, the company announced. But one of the two failed ... Read more